Expression and regulation of cyclic nucleotide phosphodiesterases in human and rat pancreatic islets. by Emilia Heimann, Helena A Jones, Svante Resjö, Vincent C Manganiello, Lena Stenson, Eva Degerman

“…As shown by transgenic mouse models and by using phosphodiesterase 3 (PDE3) inhibitors, PDE3B has an important role in the regulation of insulin secretion in pancreatic β-cells. …”
Get full text

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements by Oana Ramona Cătălina Gheorghiu, Anne Marie Ciobanu, Claudia Maria Guțu, Carmen Lidia Chițescu, Giorgiana Valentina Costea, Daniela Mădălina Anghel, Ana Maria Vlasceanu, Daniela Luiza Baconi

“…This study proposed a high-performance thin-layer chromatography (HPTLC) screening method to detect phosphodiesterase 5 (PDE-5) inhibitors as possible adulterant agents in various dietary supplements. …”
Get full text

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy by Mitchell S Buckley, Robin L Staib, Laura M Wicks, et al

“…We have undertaken a review of phosphodiesterase-5 (PDE-5) inhibitors in PAH with a focus on efficacy and safety. …”
Get full text

The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. by Joanna Schwenkgrub, Malgorzata Zaremba, Ilona Joniec-Maciejak, Agnieszka Cudna, Dagmara Mirowska-Guzel, Iwona Kurkowska-Jastrzębska

“…Since the degeneration of the nigrostriatal dopaminergic pathway in Parkinson's disease (PD) is associated with the inflammation process and decreased levels of cyclic nucleotides, inhibition of up-regulated cyclic nucleotide phosphodiesterases (PDEs) appears to be a promising therapeutic strategy. …”
Get full text

Docking studies: In silico phosphodiesterase inhibitory activity of commercially available flavonoids by Arumugam Madeswaran, Muthuswamy Umamaheswari, Kuppusamy Asokkumar, Thirumalaisamy Sivashanmugam, Varadharajan Subhadradevi, Puliyath Jagannath

“…The objective of the current study is to evaluate the phosphodiesterase inhibitory activity of flavonoids using in silico docking studies. …”
Get full text

Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice by Ghofrani Hossein A, Weissmann Norbert, Al-tamari Hamza M, Pullamsetti Soni S, Dumitrascu Rio, Udalov Sergey, Guenther Andreas, Voswinckel Robert, Seeger Werner, Grimminger Friedrich, Schermuly Ralph T

“…<p>Abstract</p> <p>Background</p> <p>Pulmonary fibrosis (PF) is a group of devastating and largely irreversible diseases. Phosphodiesterase (PDE) 4 is involved in the processes of remodeling and inflammation, which play key role in tissue fibrosis. …”
Get full text

Identification and characterization of a novel phosphodiesterase from the metagenome of an Indian coalbed. by Durgesh Narain Singh, Ankush Gupta, Vijay Shankar Singh, Rajeev Mishra, Suneel Kateriya, Anil Kumar Tripathi

“…Although phosphomonoesterases and phosphotriesterases have been studied in detail, studies on phosphodiesterases are rather limited. In our search to find novel phosphodiesterases using metagenomic approach, we cloned a gene encoding a putative phosphodiesterase (PdeM) from the metagenome of the formation water collected from an Indian coal bed. …”
Get full text

Phosphodiesterase 8A Regulates CFTR Activity in Airway Epithelial Cells by Mark J. Turner, Yukiko Sato, David Y. Thomas, Kathy Abbott-Banner, John W. Hanrahan

Get full text

Apicomplexan phosphodiesterases in cyclic nucleotide turnover: conservation, function, and therapeutic potential by William J. Moss, Lorenzo Brusini, Ronja Kuehnel, Mathieu Brochet, Kevin M. Brown

Subjects: “…phosphodiesterase…”
Get full text

APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION by T. V. Martynyuk, Z. H. Dadacheva, V. M. Paramonov, O. A. Arkhipova, S. N. Nakonechnikov, I. Ye. Chazova

“…Randomized trials showed a beneficial effect of phosphodiesterase type 5 (PDE-5) inhibitors on vascular remodelling and vasodilatation in pulmonary arterial hypertension (PAH). …”
Get full text

Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions by Daniëlle M. Coenen, Alexandra C. A. Heinzmann, Silvia Oggero, Hugo J. Albers, Magdolna Nagy, Perrine Hagué, Marijke J. E. Kuijpers, Jean-Marie Vanderwinden, Andries D. van der Meer, Mauro Perretti, Rory R. Koenen, Judith M. E. M. Cosemans

Subjects: Get full text

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management? by Nicola Mondaini

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. by Pathan, E, Abraham, S, Van Rossen, E, Withrington, R, Keat, A, Charles, P, Paterson, E, Chowdhury, M, McClinton, C, Taylor, P

“… OBJECTIVES: To evaluate the efficacy and safety of an oral phosphodiesterase 4 inhibitor, apremilast, in treatment of ankylosing spondylitis (AS) by monitoring symptoms and signs in a pilot study including exploratory investigation of effects of PDE4 inhibition on blood biomarkers of bone biology. …”

INHIBITION OF PHOSPHODIESTERASE 4 PROMOTES DIFFERENTIATION AND FUSION OF BEWO CHORIOCARCINOMA CELLS by Collett, G, Fotaki, E, Redman, C, Sargent, I

A complex phosphodiesterase system controls β-adrenoceptor signalling in cardiomyocytes by Mongillo, M, Zaccolo, M

“…Given the large diversity of PKA targets within cardiac cells, a precisely regulated and confined activity of such signalling pathways is essential for the specificity of response. PDEs (phosphodiesterases) constitute the only cAMP-degrading mechanism and are expressed in the cardiomyocyte in at least 5 family variants. …”

A complex phosphodiesterase system controls beta-adrenoceptor signalling in cardiomyocytes. by Mongillo, M, Zaccolo, M

“…Given the large diversity of PKA targets within cardiac cells, a precisely regulated and confined activity of such signalling pathways is essential for the specificity of response. PDEs (phosphodiesterases) constitute the only cAMP-degrading mechanism and are expressed in the cardiomyocyte in at least 5 family variants. …”

Erectogenic Effects of Clerodendron capitatum: Involvement of Phosphodiesterase Type-5 Inhibition by Abdelwahab, S.I., Mohamed, A.H., Oall, M., Mohamed, O.Y., Elhassan Taha, M.M., Mohan, S., Noordin, M.I., Mustafa, Mohd Rais, M. Alkharfy, K.

Get full text

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews by Nikolaos Pyrgidis, Nikolaos Pyrgidis, Ioannis Mykoniatis, Ioannis Mykoniatis, Anna-Bettina Haidich, Maria Tirta, Persefoni Talimtzi, Dimitrios Kalyvianakis, Dimitrios Kalyvianakis, Andreas Ouranidis, Andreas Ouranidis, Dimitrios Hatzichristou, Dimitrios Hatzichristou

Subjects: “…phosphodiesterase type 5 (PDE5) inhibitors…”
Get full text

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update by Wen-Hao Zhang, Xin-Hua Zhang

Subjects: “…benign prostatic hyperplasia; erectile dysfunction; overactive bladder; phosphodiesterase isoenzymes 5 inhibitor; priapism; smooth muscle…”
Get full text

5'-Ribonucleotides production using 5'-phosphodiesterase from spent malt roots by Edson Marcelino Alves, Joyce Faria de Souza, Szymon Macieja, Pedro de Oliva Neto

“…The present work aims to produce a composition of 5’-ribonucleotides using spent brewer’s yeast as cheap source of RNA, and barley malt rootlets as cheap source of 5'-phosphodiesterase (5'-PDE). This is a very promising and innovative strategy because both spent yeast and malt rootles are residues of the brewing process and are closely linked in a cycle that until now is not yet commercially exploited due to lack of studies. …”
Get full text